Skip to main
AGEN

Agenus (AGEN) Stock Forecast & Price Target

Agenus (AGEN) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Agenus is valued positively at $25 per share through a DCF analysis. While risks exist due to safety concerns, efficacy, and competition, the company has a differentiated pipeline with potential for value creation. This includes the potential for a patent extension, consistent and strong results in clinical trials, and a favorable safety profile in comparison to other treatments. These factors, along with the potential for achieving the necessary pCR for a positive outcome in the ROBBIN trial, support a positive outlook for the company's stock.

Bears say

Agenus is continuing to rely heavily on pre-commercial revenues, while posting an EPS of ($0.01) for 2Q26 due to operating expenses of $23.2M may prove detrimental in the long-term, as the company’s shift in strategy to the neoadjuvant setting may result in increased operating expenses and reliance on future financing. Additionally, risks to achieving the $25 PT include potential safety or efficacy issues, increased competition, changes to current programs and regulatory concerns.

Agenus (AGEN) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Agenus and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Agenus (AGEN) Forecast

Analysts have given Agenus (AGEN) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Agenus (AGEN) has a Strong Buy consensus rating as of Sep 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Agenus (AGEN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.